ENT

Verana Health to Reveal Results from Largest Pediatric Intraocular Lens Study, Funded by the FDA, During AAPOS 2024

Retrieved on: 
Tuesday, April 9, 2024
Device, Intraocular lens, IOL, CDRH, Health equity, Partnership, Patient, SAN, Research, American Academy, Manuscript, MD, ENT, Quality, Safety, FDA, Cataract, Food, Medicine, Dentistry

Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.

Key Points: 
  • Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.
  • “The results of this study underscore the transformative potential of high-quality, curated real-world data in generating real-world evidence to enhance treatments and improve patients’ lives,” said Sujay Jadhav, CEO of Verana Health.
  • “We thank the FDA for the opportunity to lead this study, and we extend our appreciation to the Academy for its partnership.
  • Verana Health utilized its clinician-directed and artificial intelligence-enhanced population health data engine, VeraQ ®, to analyze curated, de-identified IRIS Registry data on pediatric cataract surgeries, amplifying the depth and accuracy of the study's insights.

Lead Real Estate Co., Ltd ENT TERRACE AKIHABARA Hotel Recognized for Booking.com’s Traveller Review Awards 2024

Retrieved on: 
Monday, April 8, 2024
Travel, Electronics, Booking.com, ENT, Safety, LRE, Tokyo City, Hotel

Booking.com’s Traveller Awards is an esteemed list of international properties based on over 308 million customer reviews.

Key Points: 
  • Booking.com’s Traveller Awards is an esteemed list of international properties based on over 308 million customer reviews.
  • The final review score was calculated on December 1, 2023, based on reviews received in the previous three years.
  • “Our ENT TERRACE AKIHABARA property, which opened to customers in February 2023, demonstrates our continued dedication to developing exceptional properties and experiences for long-term travel.
  • This is the second hotel that the Company has developed for the ENT TERRACE brand, with the other one located in Asakusa.

Optinose to Present at the Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 4, 2024
Nose, Webcast, Patient, Ear, OPTN, Conference, ENT, Broadcasting

YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m.

Key Points: 
  • YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m.
  • ET.
  • To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.
  • A replay of the webcast will be available for 30 days following the conclusion of the event.

Integra LifeSciences Completes the Acquisition of Acclarent, Inc.

Retrieved on: 
Monday, April 1, 2024
Nose, Ear, Integra, Acquisition, Neurosurgery, ENT

PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc. , a pioneer in ear, nose and throat (ENT) surgical interventions.

Key Points: 
  • PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc. , a pioneer in ear, nose and throat (ENT) surgical interventions.
  • The addition of Acclarent's innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel.
  • The acquisition adds $1 billion to the total addressable market of the Company’s offerings, while providing unique market opportunities for access to the attractive ENT device segment.
  • A webcast replay of the conference call will be posted on the investor section of the Company’s website following the call.

Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope

Retrieved on: 
Wednesday, March 27, 2024
ICG, Diagnosis, MRI, Anatomy, Fluorescence, Neurosurgery, ENT, Indocyanine green, Lighting, LED, Blood, FDA, Food, Microscope

Near-Infrared fluorescence now available on Modus X robotic exoscope, complementing system’s existing advanced fluorescence capabilities

Key Points: 
  • Near-Infrared fluorescence now available on Modus X robotic exoscope, complementing system’s existing advanced fluorescence capabilities
    TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, has received 510(k) clearance from the Food and Drug Administration (FDA) for its Near-Infrared fluorescence visualization module, Modus IR, adding to the existing fluorescence offering on its 4K 3D robotic exoscope, Modus X.
  • Synaptive’s Modus X features a unique fluorescence feature, powered by customized LED lighting, that enables a live fusion of white light and fluorescence views.
  • This enables visualization of fluorescent tissue and surrounding anatomy simultaneously to provide additional anatomical context while performing complex microsurgical techniques.
  • ICG causes blood to fluoresce under infrared light and is used to aid in the visualization of vessels and blood flow.

OM1 and Medtronic Partner on Propel Study to Assess Long-term Outcomes for Patients With Chronic Rhinosinusitis

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, General Health, Pharmaceutical, Health Technology, Research, Artificial Intelligence, Surgery, Science, University Challenge 2013–14, Partnership, Physician, Inflammation, Patient, American Academy, Standard of care, CRS, AI, Medtronic, PROPEL, ENT, Sinusitis, ESS, Adhesion, Pharmaceutical industry

The study focused on healthcare resource use (HCRU) and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS).

Key Points: 
  • The study focused on healthcare resource use (HCRU) and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS).
  • The study found that PROPEL devices are associated with lower HCRU and revision surgery during a 24-month follow-up period after ESS.
  • Thus, the use of PROPEL devices may lead to payer savings from reduced healthcare resource utilization.
  • “The results of this study demonstrate a rare win-win-win within healthcare,” said Amy Van Sach, president of Medtronic ENT.

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Retrieved on: 
Friday, March 15, 2024
Nosebleed, Research, Polyp (medicine), Vanderbilt University, Sciatica, Fluticasone, Education, Drainage, Disease, Incidence, Headache, Inflammation, Patient, Conditional sentence, Chronic obstructive pulmonary disease, Sinusitis, CRS, Standard of care, Quality of life, Migraine, Nasal cavity, Ear, ENT, Service, MPH, Nose, OPTN, FDA, Frustration, Food, Pharmaceutical industry

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Key Points: 
  • Chronic sinusitis (also called “chronic rhinosinusitis” or “CRS”) is one of the most common chronic diseases, affecting approximately 30 million adults in the United States.
  • Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine.
  • Chronic sinusitis is also one of the most common diagnoses in adult outpatient medicine.
  • Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually.

Spirair, Developer of the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation, Announces Appointment of Benjamin Bishop as Chief Executive Officer

Retrieved on: 
Tuesday, March 12, 2024
Surgery, Medical Devices, Health, Health Technology, Medical Supplies, NSD, Clinical Otolaryngology, PMID, Patient, Acquisition, NSR, Stanford University, NAO, Otorhinolaryngology, ENT, Therapy, Septum, Marketing, IRB, Pharmaceutical industry

Spirair™, an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients, today announced the appointment of Benjamin Bishop as its chief executive officer.

Key Points: 
  • Spirair™, an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients, today announced the appointment of Benjamin Bishop as its chief executive officer.
  • The company is developing a novel therapy for symptomatic nasal septal deviation (NSD) that supports and straightens minor deviations in the septum with a bioabsorbable implant.
  • Treatment options for symptomatic NSD have been limited to either over-the-counter medications to alleviate symptoms or invasive surgical techniques to address the structural issues that cause these symptoms.
  • were co-fellows in the program and identified an opportunity in the ENT space when they discovered the unmet need for a minimally invasive nasal septal deviation correction therapy to help address nasal airway obstruction.

EARLENS ANNOUNCES APPOINTMENT OF ROBERT GLAZER AS STRATEGIC ADVISOR

Retrieved on: 
Monday, April 1, 2024
Audiology, Private practice, ENT, Hearing loss, Multimedia, Marketing, Physician, Hearing, Otorhinolaryngology, Pharmaceutical industry

MENLO PARK, Calif., April 1, 2024 /PRNewswire/ -- Today, EARLENS, a leader in innovative Hearing Technology and Virtual Clinical Diagnostic Delivery Platforms, proudly announces the appointment of Robert Glazer as a Strategic Advisor to the company. Glazer, well known in the Otolaryngology, Allergy and Audiology space will play a key role in advancing the promotion of EARLENS' groundbreaking hearing solutions. 

Key Points: 
  • MENLO PARK, Calif., April 1, 2024 /PRNewswire/ -- Today, EARLENS, a leader in innovative Hearing Technology and Virtual Clinical Diagnostic Delivery Platforms, proudly announces the appointment of Robert Glazer as a Strategic Advisor to the company.
  • Glazer, well known in the Otolaryngology, Allergy and Audiology space will play a key role in advancing the promotion of EARLENS' groundbreaking hearing solutions.
  • As the company continues to push the boundaries of hearing technology and care delivery, EARLENS recognizes the value of Glazer's extensive experience.
  • "We are thrilled to welcome Robert Glazer to the EARLENS family as a strategic advisor," said J. Connon Samuel, Chief Operating Officer at EARLENS.

Aohua Endoscopy's AQ-300 is Recognized as "Endoscopy Product Innovation Award" by the Healthcare Asia Medtech Awards 2024

Retrieved on: 
Friday, March 29, 2024
Biopsy, CBI, Health, ENT, Endoscopy, Observation, Urology, Gastroenterology, Telescopic sight

SINGAPORE, March 29, 2024 /PRNewswire/ --  Medical equipment manufacturing company Aohua Endoscopy clinched the Endoscopy Product Innovation Award at the recently held Healthcare Asia Medtech Awards 2024 for its development of the Aohua 4K AQ-300 video endoscopy system, which offers an improved endoscopic diagnosis and treatment option.

Key Points: 
  • SINGAPORE, March 29, 2024 /PRNewswire/ --  Medical equipment manufacturing company Aohua Endoscopy clinched the Endoscopy Product Innovation Award at the recently held Healthcare Asia Medtech Awards 2024 for its development of the Aohua 4K AQ-300 video endoscopy system, which offers an improved endoscopic diagnosis and treatment option.
  • The awards program recognizes outstanding medical technology companies in Asia that are influencing the transformation of healthcare by excelling in medical device innovation, service delivery, and patient care.
  • When used in conjunction with Aohua's magnification endoscope, AQ-300 can guarantee that the image is clear even at high magnification.
  • It features dual-frame display support, which enables simultaneous observation of the same location in modes with CBI and white light.